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Abstract
Aims/Hypothesis: We have previously shown the implication of the multifunctional protein SPARC (Secreted protein acidic
and rich in cysteine)/osteonectin in insulin resistance but potential effects on beta-cell function have not been assessed. We
therefore aimed to characterise the effect of SPARC on beta-cell function and features of diabetes.
Methods: We measured SPARC expression by qRT-PCR in human primary pancreatic islets, adipose tissue, liver and muscle.
We then examined the relation of SPARC with glucose stimulated insulin secretion (GSIS) in primary human islets and the
effect of SPARC overexpression on GSIS in beta cell lines.
Results: SPARC was expressed at measurable levels in human islets, adipose tissue, liver and skeletal muscle, and
demonstrated reduced expression in primary islets from subjects with diabetes compared with controls (p,= 0.05). SPARC
levels were positively correlated with GSIS in islets from control donors (p,= 0.01). Overexpression of SPARC in cultured
beta-cells resulted in a 2.4-fold increase in insulin secretion in high glucose conditions (p,= 0.01).
Conclusions: Our data suggest that levels of SPARC are reduced in islets from donors with diabetes and that it has a role in
insulin secretion, an effect which appears independent of SPARC’s modulation of obesity-induced insulin resistance in
adipose tissue.
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Introduction
The SPARC gene encodes a multifunctional matricellular
protein which modulates the interaction between cells and the
extra-cellular matrix (ECM) by the regulation of factors such as
collagen and vitronectin [1]. SPARC has roles in many processes,
including wound healing, inflammation, extracellular protease
activity, angiogenesis, remodelling of cardiac muscle and modu-
lation of growth factor signalling [2]. Alterations to SPARC levels
or activity have been associated with several common human
diseases such as osteoporosis [3], arthritis [4,5], cancer [6], heart
disease [7,8], obesity [8,9], and independent of obesity, type 2
diabetes [10,11]. SPARC is expressed at relatively high levels in
most tissues, but particularly in adipose tissue, where it inhibits
adipogenesis [12,13].
The influence of SPARC in insulin resistance and type 2
diabetes may arise from its role in the regulation of collagen
assembly and ECM remodelling [14,15]. SPARC is expressed and
secreted from adipose tissue at higher levels in obese individuals
than in lean individuals [9], furthers ECM fibrosis which in turn
impairs adipocyte differentiation and adipose tissue expansion
[10,16]. Restriction of adipose tissue expansion in combination
with surplus dietary lipid exposure leads to systemic hyperlipid-
aemia and ultimately triglyceride infiltration of other organs, as
ectopic fat [12] which furthers insulin resistance. SPARC
circulating levels are associated with HOMA-IR [9] and HbA1c
[17] in obese individuals without diabetes and secretion from
adipose tissue is induced by insulin. These data point to an
important role for SPARC in insulin resistance. SPARC also has
potential to act as a regulator of insulin secretion or in
maintenance of beta-cell function. It is known to be involved in
WNT signalling, which is important in control of cell-cell
communication and cellular proliferation and differentiation
[18], and also regulates several genes involved in beta-cell
development or islet neogenesis [19,20,21] and is also known to
regulate cell survival [22,23]. These observations make SPARC an
interesting candidate as a modifier of islet insulin secretory
capacity, since both destruction and dedifferentiation of beta cells
has been described in type 2 diabetes [24,25].
The overall aim of this study is to provide evidence of SPARC’s
role on beta-cell function in human physiology and study of
primary human tissues. We aimed to assess the potential for
SPARC to be involved in insulin secretion, by examining SPARC
expression in relation to not just diabetes status but also glucose
stimulated insulin secretion in primary human islets, and by
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assessing the effects of overexpression of SPARC on glucose
stimulated insulin secretion (GSIS) in cultured rat beta cells.
Materials and Methods
Samples Used for Analysis
Human omental fat samples were obtained from subjects
undergoing elective surgical procedures and collected via the
Peninsula NIHR Clinical Research Facility human tissue bank.
Samples for analyses of SPARC expression in liver and skeletal
muscle were obtained as part of the tissue panel described below.
Human islet samples were obtained from Procell Biotech (Newport
Beach, USA). All islet samples were cultured overnight at source
and scored for islet purity and viability. Islet preparations from this
source were supplied with full clinical information, most impor-
tantly including glucose stimulated insulin secretion (GSIS) index
measures following ELISA analysis. This is a measure of the ratio
of insulin produced at 28 mM glucose compared with 2.8 mM
glucose as described in Ihm et al, 2006 [26]. Characteristics of the
islet donors are given in table 1.
Ethics Statement
Ethical permission was granted from the South West Devon and
Torbay Research Ethics Committee, for the human omental
adipose samples. Written consent was obtained for all participants
and agreed by the ethics board. All samples were treated, stored
and processed according to the Declaration of Helsinki and
Human Tissue Act regulations.
RNA Preparation and Reverse Transcription
RNA was extracted from human omental adipose samples using
the RNAeasy mini lipid extraction kit as recommend by the
manufacturer (Qiagen, Crawley, UK). Liver and skeletal muscle
samples were obtained directly as isolated RNA from AMS
Biosciences (Abingdon, UK). RNA was extracted from primary
human islets using the mirVana kit (Life Technologies, California,
USA). All RNA samples were DNAse treated using the TURBO
DNAse kit (Life Technologies, California, USA) prior to analysis,
according to the manufacturer’s instructions. RNA samples were
reverse transcribed using the Superscript III cDNA synthesis kit
(Life Technologies, California, USA) in a volume of 20 ml,
according to the manufacturer’s instructions.
Design and Validation of a TaqMan Assay to Detect
SPARC mRNA
A TaqMan assay was designed to the SPARC mRNA and
purchased from the Assays-by-Design service available from Life
technologies (California, USA). Probe and primer sequences are
available on request. Assays were validated by 1 in 2 serial
dilutions of pooled cDNA from multiple tissues to construct
standard curves. Reactions were carried out on the ABI Prism
7900HT platform using SDS v2.3 software (Life Technologies,
California, USA). Reactions contained 10 pl TaqMan Universal
Mastermix (no AMPerase) (Applied Biosystems, Foster City, USA),
0.9 mM each primer, 0.25 mM probe and 2 ml cDNA reverse
transcribed as above in a total volume of 20 ml. Cycling conditions
were 50 cycles of 95uC for 10 mins, 15 seconds at 95uC and 1 min
at 60uC using a 20 ml sample volume. The efficiency of the assay
as determined from the curve gradient and the correlation
between cDNA concentration and crossing point (r2 value) were
assessed from the standard curves. The efficiency of amplification
as given by the gradient of the standard curve was 23.7 and
accuracy of quantification as given by the correlation co-efficient
r2 was 0.99.
Profiling of SPARC Expression in Human Tissues Relevant
to Diabetes
SPARC expression was measured in pooled adipose tissue
(n = 4), individual pancreatic islet samples (n = 8) and pooled liver
(n = 1) and pooled muscle (n = 7). Expression profiles for SPARC
were calculated by reference to the average crossing point of three
replicates for each sample, relative to the mean crossing point of
three separate endogenous control genes (TBP, GUSB and B2M).
Endogenous control genes were selected on the basis that their
expression did not vary according to the parameters to be tested.
Reaction conditions were as outlined above. Expression levels
were calculated by the Comparative Ct method [27], and
normalised to the levels of SPARC in adipose tissue.
SPARC Expression According to Diabetes Status in
Human Primary Islets
The expression level of SPARC mRNA was determined relative
to 3 endogenous control genes in human primary islet samples
from control individuals and from those with type 2 diabetes
(participant characteristics are given in table 1). For this analysis,
SPARC expression was calculated in individual islet samples.
Endogenous control genes (TBP, GUSB and B2M), reaction and
cycling condition were as described above. SPARC transcript levels
were normalised to the median DCt for SPARC in the control
samples. To account for the possibility that any expression
differences could be due to potential reductions in beta cell mass
in the islets from donors with diabetes [28], we also measured the
expression of two genes with high expression in islets; phogrin
(PTPRN2) and glucokinase (GCK). The association between
diabetes status and the expression level of SPARC was assessed
by Mann Whitney-U analysis. Non-parametric statistics were used
to account for the low sample numbers.
SPARC Expression and Basal Insulin or GSIS in Primary
Human Islets from Individuals without Diabetes
SPARC expression in samples from control primary human islets
(n = 23) was assessed by reference to the average crossing point of
three replicates for each sample, relative to the mean crossing
point of three separate endogenous control genes (TBP, GUSB and
B2M). Reaction conditions were as outlined above. SPARC
expression levels were normalised to median DCt for SPARC
Table 1. Characteristics of donors and samples for human
primary islet collection.
Parameter
Non-diabetic
subjects Diabetic subjects
N 23 4
Sex (M/F) 10/13 3/1
Age (years) 39 (10.79) 52.75 (7.54)
Disease Duration (years) N/A 2.665 (1.89)
BMI 30.2 (7.75) 39.6 (17.89)
Islet purity (%) 87 82
Islet viability (%) 91 93
M=Male, F = female, N =number of samples tested. BMI = Body Mass Index.
HbA1c =Glycosylated haemoglobin.
doi:10.1371/journal.pone.0068253.t001
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across all the samples. Associations between SPARC expression and
the increment in insulin secretion in response to a 28 mM glucose
challenge as detailed in [26] were assessed by using linear
regression on transformed data, adjusted for BMI. Since SPARC
expression has previously been found to be positively regulated by
insulin itself in adipose tissue [9], linear regression analysis
adjusted for BMI was also carried out on the basal insulin
measurement to assess the contribution of any regulatory effect of
insulin in islets. A Bonferroni correction was carried out to control
for multiple testing, since we were correlating SPARC expression
with two outcome measures; insulin SI and basal insulin levels. A
p-value of ,=0.025 was thus considered statistically significant.
Overexpression of SPARC in Cultured Rat Beta Cells
Rat INS-1 beta cells were grown in RPMI-1640 medium
containing 11 mM glucose, 10% foetal bovine serum, 2 mM L-
glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.
Cells were cultured at 37uC in 5% CO2 and were grown and
maintained in 75-cm3 flasks. They were analysed or passaged
when approximately 80% confluent.
Empty plasmid [pLNCX2] and plasmid containing the human
SPARC construct were kindly provided by Dr David Allard,
University of Exeter Medical School. To establish stable overex-
pression of SPARC, INS cells were seeded at 0.56106cells/well and
allowed to attach for 24 hrs before transfection with 5 mg plasmid
DNA in the presence of TransFast transfection reagent (Promega,
Southampton, UK). Cells were grown in media supplemented
with 0.15 mg/ml G418 (Invitrogen, Paisley, UK) to allow positive
selection of transfected cells and creation of stable cell lines. Non-
transfected INS cells cultured with G418 were used as a control for
antibiotic efficiency. Two independent transfections were per-
formed using the SPARC vector and empty vector respectively.
Quantitative Real-time PCR Confirmation of SPARC
Overexpression
Total RNA was extracted from SPARC transfected and empty
vector transfected cells using the guanidinium-thiocyanate-phenol-
chloroform extraction method [29]. Briefly, cells were homoge-
nised by passing gently through a 21G needle in 1 ml Tri reagent
(Life Technologies, California, USA) and RNA precipitated in line
with manufacturer’s instructions. RNA quantity and purity was
assessed spectrophotometrically using Nanodrop technology.
Genomic contamination was removed from RNA using DNase I
(Fermentas, Loughborough, UK) before 500 ng RNA was reverse
transcribed using a Superscript VILO cDNA synthesis kit (Life
Technologies, California, USA) in line with the manufacturer’s
protocol.
cDNA was diluted 1:2 in 0.01 M Tris HCl and all samples
amplified in triplicate using expression assays specific for human
(Hs00234160_m1) and rodent (Rn01470624_m1) SPARC. Gene
expression levels were determined using the comparative Ct
method [27], calibrating to SPARC expression within transfected
cells (figure S1).
Assessment of Insulin Secretion in Transfected Beta Cells
INS-1 cell lines expressing either pLNCX2 empty vector, or
pLNCX2 hSPARC, were seeded in 24 well plates at 0.56106 cells/
well and left to attach for 24 hrs. Cells were then pre-incubated
with 0.5 ml of KREBs ringer buffer solution (125 mM NaCl,
4.74 mM KCl, 1 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM
MgSO4, 5 mM NaHCO3, 25 mM Hepes, pH 7.4) containing
0.1% BSA and 2.8 mM glucose. Cell were then washed and
acutely stimulated with 2.8 mM, 5.6 mM and 16.7 mM glucose or
a combination of 100 mM IBMX (Sigma, Dorset, UK) and 2 mM
forskolin (Sigma, Dorset, UK). After 1 hr media was sampled to
measure insulin levels using a radioimmunoassay (individual
reagents from Sigma, Dorset, UK), with radioactive insulin
sourced from Millipore. The cells were washed in 0.5 ml of
PBS, before the addition of 1 M NaOH, shaken at room
temperature for 2 hrs, and the lysate used in a BCA assay (Pierce,
Rockford, USA) to determine protein content. Insulin secretion
levels were expressed as ng insulin/mg protein per well before
normalising to insulin secretion at 2.8 mM glucose to give a
stimulation index. Results were examined for statistical signifi-
cance by 2-tailed t-test.
Results
SPARC mRNA is Present at Measurable Levels in Tissues
Relevant to Diabetes
SPARC mRNA was present at detectable levels in adipose tissue,
pancreatic islets, skeletal muscle and liver (figure 1). Levels of
SPARC were highest in adipose tissue and skeletal muscle, but were
present at lower levels in the pancreatic islet and liver.
SPARC Expression is Lower in the Primary Islets of People
with Diabetes
SPARC was expressed at lower levels in primary islet samples
from donors with diabetes compared with those from control
donors. The mean expression levels of SPARC relative to the
endogenous control genes was found to be 1.19 in control islets,
compared with 0.43 in the islets from subjects with diabetes;
p = 0.049. We found no differences in the expression levels of
either Phogrin or Glucokinase between islet samples from subjects
with and without diabetes (p = 0.83 and p= 0.53 respectively)
which suggests no significant reduction in islet cells in subjects with
diabetes. Circulating SPARC is known to increase in obesity on
the basis of increased expression and secretion of SPARC in
adipose tissue [9]. Whilst donors with diabetes had a higher BMI
than control donors, no significant increase of SPARC expression
due to increased BMI was noted in our samples.
Figure 1. The expression profile of human SPARC. The expression
patterns of SPARC mRNA in human adipose, pancreatic islet, liver and
muscle tissues are given relative to the TBP, GUSB and B2M endogenous
control genes. Expression level of SPARC in each tissue is expressed
relative to SPARC levels in adipose tissue. Error bars are derived from the
interquartile range of quantification.
doi:10.1371/journal.pone.0068253.g001
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SPARC Expression is Correlated with Glucose-stimulated
Insulin Secretion in Primary Islets
SPARC expression was positively correlated with glucose
stimulated insulin secretion (GSIS) index measures as determined
by ELISA analysis (table 2; figure 2). The beta coefficient following
linear regression analysis adjusted for BMI was 0.68; p = 0.007. In
contrast to the situation in adipose tissue, we found no correlation
of SPARC expression with basal insulin levels pre-glucose
challenge; beta coefficient 20.43, p= 0.153 (table 2).
Overexpression of Human SPARC in INS-1 Cells Increases
Glucose-stimulated Insulin Secretion
The rat pancreatic b-cell line, INS-1 was used to directly
determine the influence of SPARC on insulin secretion. Two
independent stably transfected INS-1 cell lines pLNCX2
SPARC#1 and pLNCX2 SPARC#2, overexpressing human
SPARC were created (see figure S1). The SPARC overexpressing
cells showed an 2.4-fold increase in insulin secretion stimulated by
16.7 mM glucose (Stimulation Index 5.8 compared with 2.4 in
vector-only cells; p = 0.002), but not 2.8 mM glucose or 5.6 mM
glucose compared to empty vector control cells (figure 3),
suggesting that its effects are specific to high glucose concentra-
tions. SPARC overexpressing cells also demonstrated an 1.6-fold
increase in insulin secretion in response to stimulation by IBMX/
forskolin (Stimulation Index 5.6 compared with 3.5; p = 0.004;
figure 3).
Discussion
In this study we report a potential novel role for the
matricellular protein SPARC in moderation of insulin secretion
in pancreatic islets. The SPARC gene is expressed at detectable
levels in primary human islets and was found to be lower in the
islets of patients with type 2 diabetes, despite a higher BMI in these
subjects. SPARC expression was also positively correlated with
glucose-stimulated insulin secretion (GSIS), in human primary islet
cultures. Furthermore, overexpression of SPARC, in cultured rat
beta cells (INS-1) resulted in a 2.4-fold increase in glucose
stimulated insulin secretion compared to control cells. Insulin
secretion stimulated by IBMX/forskolin in INS-1 cells was also
potentiated by SPARC overexpression.
SPARC is known to be induced by insulin in human adipose
tissue [9]. Interestingly, in our study, we found no evidence that
SPARC expression level was correlated with basal insulin levels in
primary human islets (table 2). In adipose tissue, insulin levels are
positively correlated with SPARC levels in adipose tissue [9],
whereas we have found that basal insulin is negatively correlated
with SPARC expression in human islets, indicating some degree of
tissue specificity. This is entirely consistent with a known feature of
SPARC function, in that it can play apparently opposing roles
depending on the cell type and intercellular environment [30].
Whilst the expression levels of SPARC were lower in islets from
donors with diabetes, this may not necessarily impact on the
function of SPARC in the islet or could indicate a consequence of
altered splicing induced by a disturbance in glucose or lipid
homeostasis, which will need to be further evaluated in subsequent
studies.
SPARC could be playing a part in moderation of beta-cell
function by several potential mechanisms. Our observation that
insulin secretion is increased in SPARC-transfected rat beta cells in
response to IBMX/Forskolin may suggest that the mode of action
may involve alternative regulatory pathways such as the amplifi-
cation pathway [31], although this suggestion would require more
experimental evidence to prove definitively, and will form the basis
for future studies. The amplification pathway acts by increasing
the effect of high cellular calcium on insulin vesicle exocytosis once
glucose has reached a threshold value. The amplification pathway
is known to be impaired in beta-cells of animal models of type 2
diabetes and there is also some evidence that it may also be
Table 2. Glucose stimulated insulin secretion and basal insulin according to SPARC expression in primary human islet cultures.
Transcript
Effect size (beta co-
efficient) Standard Error p-value
Correlation co-efficient
(r2)
Glucose stimulated insulin increment
SPARC 0.68 0.165 0.007 0.54
Basal insulin
SPARC 20.43 0.227 0.153 0.24
Associations between Glucose-stimulated insulin secretion and basal insulin levels were assessed by linear regression analysis, adjusted for BMI. Significant associations
are indicated in bold italic type.
doi:10.1371/journal.pone.0068253.t002
Figure 2. The association of SPARC expression on glucose
stimulated insulin secretion in primary human islets. The figures
on the Y axis refer to insulin stimulation index (SI) following a 28 mM
glucose challenge. The expression level of SPARC is given on the X axis.
Expression levels were calculated relative to the endogenous controls
GUSB, B2M and PP1A and normalised to the mean level of SPARC across
the cohort.
doi:10.1371/journal.pone.0068253.g002
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affected in the islets of patients with type 2 diabetes [31]. This is
concordant with our own observations that SPARC expression is
reduced in the islets of patients with type 2 diabetes.
SPARC is also known to have roles as a survival factor. Studies
in fruit flies have demonstrated that cells can secrete SPARC in
response to apoptotic stimuli, which protects them from cell death
[32]. This has been confirmed in human studies in breast cancer,
where SPARC has been shown to cause the AKT-mediated
phosphorylation of theMDM2 gene product, and subsequently the
negative regulation of the tumour suppressor p53 [22]. Apoptosis
is thought to be one of the major factors in decline of beta cell
mass in both type 1 and type 2 diabetes [33] and the failure of beta
cell mass to expand in order to compensate for increasing insulin
resistance is another key factor in the development of type 2
diabetes [34]. SPARC has also been shown to have proliferative,
as well as anti-apoptotic effects; depletion of SPARC by siRNA
technology has been demonstrated to cause cell cycle arrest by
activation of p53 and the p21Cip1/Waf1 pathway in melanoma
cells [35].
SPARC could also be affecting beta-cell function by affecting
the differentiation state of pancreatic beta cells. Beta cell
development in embryogenesis, and also neogenesis of beta cells
as a response to insulin resistance is known to be influenced by the
activity of several metalloproteinases [20,21]. This is an important
group of proteins that are involved in the degradation and
remodelling of the extracellular matrix and have previously been
demonstrated to be regulated by SPARC [19]. Again, dedifferen-
tiation of pancreatic beta cells to more embryonic forms has been
described to be a feature of type 2 diabetes in both mouse and man
[24]. In addition to its role in the regulation of MMP genes,
SPARC has also been shown to regulate the activity of the
NOTCH/STAT3 pathway [36]. This is relevant because of the
recent data implicating elevated Notch and related signalling
pathways in the dedifferentiation of beta cells in type 2 diabetes
[37].
Finally, SPARC also has a role in WNT signalling. SPARC has
been shown to enhance the accumulation and nuclear transloca-
tion of beta-catenin resulting in the activation of its partner genes
such as TCF4 (TCF7L2) [13]. This is noteworthy since polymor-
phisms in the TCF7L2 gene have been demonstrated in genome
wide association studies (GWAS) to show the largest association
with susceptibility to type 2 diabetes in several populations [38]
and have also been demonstrated to influence insulin exocytosis in
human and rodent islets and in cell lines [39,40]. Interestingly,
several other genes in pathways regulated by SPARC (cell cycle/
survival; TP53, metalloproteinase activity; ADAMTS9 and beta-cell
differentiation/neogenesis; NOTCH2) are represented in the
GWAS for type 2 diabetes [38].
The strength of this study is the identification of a potential
novel role for SPARC in the regulation of insulin secretion
relevant for the onset of Type 2 diabetes. This may oppose the role
of SPARC in adipose tissue where it is thought to increase fibrosis
by increased deposition of insoluble collagen fibers, in contrast
islets of patients with diabetes are not characterised by collagen
deposition but an accumulation of amyloid (Clark A, 2001). The
adipose tissue fibrosis furthers ectopic deposition of triglycerides in
inappropriate tissues [10,16]. Whilst obesity related adipose tissue
fibrosis may well attribute to insulin resistance as also shown by
increased levels of ECM components such as collagen VIalpha3
[41], the multifunctional protein SPARC appears to influence
more than one pathway of glucose and insulin metabolism. In line
with this, a reduction in SPARC activity has also been associated
with altered glucose metabolism. SPARC knockout mice demon-
strate retarded glucose uptake following feeding and an impaired
intraperitoneal glucose tolerance test [42]. In addition, recent
studies have found a role for SPARC in the regulation of GLUT4-
Figure 3. Changes in the insulin stimulation index in SPARC-transfected rat beta cells under different glucose conditions. The figure
shows the stimulation index (SI) of transfected rat beta cells (INS-1) in response to 2.8 mM, 5.6 mM and 16.7 mM glucose or IBMX/forskolin. Results
from cells transfected with empty vector are given in light grey, and those from SPARC-transfected cells are given in dark grey. Error bars represent
standard error of measurements. Data are combined results from the two transfected cell lines. Statistical significance is indicated by stars.
doi:10.1371/journal.pone.0068253.g003
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mediated glucose transport, by modification of AICAR-mediated
phosphorylation of AMPK, where the relationship between
SPARC and AMKP is controlled by an autoregulatory loop, as
determined by siRNA studies [43].
Our results do not suggest an increase of SPARC expression in
islets of subjects with Type 2 diabetes as may have been expected
from its antiproliferative and profibrotic action in adipose tissue
[9]. After reducing the influence of obesity by BMI matching and/
or statistical adjustments for BMI in interpretation of our data and
study of expression in human islets expressions rather than
adipocytes, we found a significant reduction of SPARC expression
in islets from subjects with diabetes. This does not reflect the
pattern of adipose tissue expression of SPARC, which is positively
associated with HOMA-IR [9], or the serum levels of SPARC,
which are positively correlated with HbA1C in men without
diabetes [17] and increased in subjects with newly diagnosed
diabetes [11] and serum protein levels appear to differ from the
RNA expression in peripheral blood lymphocytes. Since adipose
tissue levels of SPARC are up-regulated by high insulin levels
(causing increased secretion of SPARC from adipose tissue to the
serum), the inverse correlation between basal insulin levels and
SPARC expression we note in control islets, may indicate that the
relationship between SPARC expression and insulin levels is
different in pancreatic islets.
To conclude, we report that the SPARC gene is expressed at
detectable levels in human primary islets, and is associated with
diabetes status and glucose stimulated insulin secretion in this
tissue. Furthermore, overexpression of SPARC in cultured rat beta
cells caused a 2.4-fold increase in insulin secretion in high glucose
conditions, which was also mirrored when the SPARC-transfected
beta cells were treated with IBMX/Forskolin. We suggest that
these data point towards a previously uncharacterised potential
role for SPARC in moderation of insulin secretion, separate from
the anti-proliferative and profibrotic function of this protein in
adipose tissue where it appears to be a moderator of insulin
resistance.
Supporting Information
Figure S1 Expression of human SPARC mRNA in
transfected beta cells. The levels of human SPARC mRNA
in INS-1 cells induced by transfection of human SPARC sequences
compared to the transfection of empty vector is given on the Y
axis, and the nature of the transfection (i.e. SPARC constructs or
empty vector) are given on the X-axis. Expression levels in each
transfected sample were normalised to the levels of SPARC
expression within SPARC transfected cells.
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